1
EXHIBIT 10.23
[Confidential treatment has been requested for portions of this exhibit. The
confidential portions have been redacted and are denoted by [**]. The
confidential portions have been separately filed with the commission.]
RESEARCH COLLABORATION AGREEMENT
BETWEEN THE
CTRC
RESEARCH FOUNDATION
AND
SANOFI
1
2
TABLE OF CONTENTS
ARTICLE I -- DEFINITIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
ARTICLE II--RESEARCH PROGRAM/PROGRAM COUNCIL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
ARTICLE III--CONSIDERATION - TERMS OF PAYMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
ARTICLE IV - OPTION RIGHT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
ARTICLE V--CONFIDENTIALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
ARTICLE VI--PUBLICATION AND PUBLICITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
ARTICLE VII--TERMINATION OR EXTENSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
ARTICLE VIII--INVENTIONS AND PATENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
ARTICLE IX--WARRANTIES AND INDEMNIFICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
ARTICLE X--INDEPENDENT CONTRACTOR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
ARTICLE M--ASSIGNMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
ARTICLE XIII--GOVERNING LAW AND ARBITRATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
ARTICLE XIV--NOTICE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
ARTICLE XIV--MISCELLANEOUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
EXHIBIT A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
LIST OF CTRC RESEARCH PROJECT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
EXHIBIT B . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
RESEARCH BUDGET SANOFI DIRECTED PROJECTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2
3
RESEARCH COLLABORATION AGREEMENT
THIS AGREEMENT, effective as of December 12, 1995 (the "Effective Date") is by
and between SANOFI, a French corporation (societe anonyme), having its
principal place of business at 00-00 xxx Xxxxxxx, 00000 Xxxxxx (hereinafter
called SANOFI, which expressions includes its affiliates, subsidiaries,
successors and assignees), represented by its President, Xxxx- Xxxxxxxx DEHECQ
and the CTRC RESEARCH FOUNDATION of 0000 Xxxxxxxxx, Xxxxx 000, Xxx Xxxxxxx,
Xxxxx 00000, U.S.A., Texas non profit corporation (hereinafter called "CTRC",
which expression includes its successors and assignees) represented by Chief
Operating Officer, Institute for Drug Development, Mr. Xxxxx XXXXXX.
WHEREAS STERLING WINTHROP Inc. (STERLING) and CTRC have previously
entered into a Research Collaboration Agreement and an Option Agreement dated
October 1, 1992;
WHEREAS STERLING and CTRC have entered into an Amendment 1 to the
Research Collaboration Agreement and an Amendment 1 to the Option Agreement,
both to the purpose of extending these Agreements through December 31, 1996,
and making certain changes to the rights and obligations of the Parties for
said calendar year 1996;
WHEREAS, CTRC and STERLING have entered into a License and Development
Agreement dated as of October 1, 1992 concerning the anticancer compound known
as MGBG,
WHEREAS STERLING, CTRC and BIOVENSA (which has changed its name to
ILEX Oncology Inc. (ILEX)) have entered into a Consent, Acknowledgement and
Waiver Agreement dated September 1994 in which CTRC, with STERLING's prior
consent, has assigned to ILEX and ILEX has accepted to assume various assets,
rights and obligations, including those of CTRC under the "MGBG License and
Development Agreement" and those of CTRC concerning the anti-cancer compound
known as Crisnatol Mesylate (Crisnatol Project);
WHEREAS SANOFI has acquired STERLING and subsequently SANOFI has
acquired all rights and obligations pertaining to the aforementioned
Agreements, and SANOFI has decided to discontinue the Crisnatol Project;
WHEREAS CTRC and SANOFI (jointly called the Parties) are desirous of
entering into a new Research Collaboration Agreement (the Agreement) which
reflects, the Parties' current needs and abilities and which, subject to terms
and conditions of this Agreement replaces and supersedes all prior Agreements
including the above mentioned Amendments between the Parties. Subsequently
SANOFI, according to the terms and conditions set forth under article IV of
this Agreement may decide, at its discretion, to enter into a License Agreement
and will study, on a case by case basis, the possibility to provide CTRC with a
related development work plan which shall be agreed upon between the Parties.
NOW, THEREFORE, in consideration of the mutual covenants contained herein,
SANOFI and CTRC agree as follows:
ARTICLE I -- DEFINITIONS
1.1 The following words and phrases shall have the following meanings:
1) (( ACQUISITION COSTS )) shall mean those necessary out-of-pockets
costs (applicable to the Field of Use)
3
4
incurred or paid by CTRC to third party from whom Commercial Rights are
acquired, to obtain Commercial Rights to any Licensed Compound or Licensed
Technology including any licensing fees, future royalty, milestone or other
payment obligations.
2) (( ANALOGUE AND COUNTERPART )) shall mean all members of a chemical
class covered by a composition of matter patent, with respect to a Lead
Compound.
3) (( ANNIVERSARY DATE )) shall mean January 1, 1996 and every January
1st thereafter throughout the term of this Agreement, including extensions
thereof.
4) (( BUSINESS DAY )) shall mean a day on which banks are open for
business in Paris, France.
5) (( COMMERCIAL RIGHTS )) shall mean CTRC's legal right by patent,
contract, agreement, copyright, trademark, or other means to make, have made,
sell or have sold in any country any Compound, material, technology or know-how
within the Field of Use for commercial purposes, including Inventions, Know-How
or Compounds. Effective January 1, 1996 Commercial Rights shall be limited to
Commercial Rights arising from the Research Program.
6) (( COMPOUND(S) )) shall mean all agents, substances or materials which
embody, in part or whole, the Inventions, Patents, Patent Application or
Know-How.
7) (( CTRC AFFILIATE )) shall mean any present or future firm, company,
joint venture or other entity which directly or indirectly is controlled by or
is under the common control of CTRC. "Control" shall mean the legal power to
direct or cause the direction of the general management and policies of such
entity whether through ownership of at least [**] percent of voting
securities, by contract or otherwise.
8) (( CTRC INFORMATION )) shall mean information developed or otherwise
acquired by or for CTRC, including all animal and human laboratory and clinical
data, technical information, Know-How, inventions, techniques, processes,
technology, systems, formulae, results of experimentation, designs, statistics
and records which pertain to Compounds and Technology that are subject to
SANOFI's Option Right set forth in this Agreement, and all information relating
to the contents of this Agreement, including Data Information Packages, which
is necessary to effectuate the grant of license to SANOFI. Effective January
1, 1996 CIRC Information sham be limited to CTRC Information arising from the
Research Program.
9) (( DATA/INFORMATION PACKAGES )) shall mean those documents which CTRC
shall submit to SANOFI in accordance with the terms of this Agreement, if
SANOFI decides to exercise its Option Right, (described under article IV of
this Agreement) and generally will be in the following Compound/Technology
categories:
(i) Compounds which have been tested in human clinical trials.
Data/Information packages will include summaries of and access to all
regulatory filings, clinical studies to date, a description of all
Commercial Rights, preclinical data, clinical, manufacturing and
controls data and all regulatory correspondence.
(ii) Compounds which are, in CTRC's opinion, suitable for human
clinical evaluation. The Data/Information Package is intended to have
such content and quality as to be suitable for filing of an
Investigation New Drug Application (IND) with the Food and Drug
Administration (FDA) with the reasonable expectation of initiating
Phase I clinical trials in human volunteers, and will also include a
description of all Commercial Rights.
(iii) Technology which may be applied in the research and
development of Compounds within the Field of Use. For Technology to
be offered for license there should exist one or more Patent or Patent
Applications and scientific data to indicate that the technology can
immediately be applied to the discovery
4
5
and development of Compounds within the Field of Use.
Notwithstanding, the above, non-patented technology, including
know-how, may make up, in whole or in part, a Data/Information
Package.
10) ((DATE OF FIRST INVENTION )) shall mean the date as listed in the
scientific notebook code signifying the day in which the concept was first
developed and described.
11) (( FIELD OF USE )) shall mean all applications of a Licensed Compound
or Licensed Technology in the treatment and/or mitigation of cancer in humans.
12) (( FIRST COMMERCIAL SALE )) shall mean the first commercial sale in
any country after the date the New Drug Application (NDA), Compound License
Agreement (CLA) or equivalent application for a Licensed Compound is approved.
13) (( FULL PROJECT FUNDING )) is defined as the funding for the total
costs to support each project as outlined in the Research Project Plan. Full
SANOFI funding is defined as the Full Project Funding outlined in the Research
Project minus external grants.
14) (( FUNDING PERIOD )) shall mean each twelve (12) month calendar
period during which SANOFI makes payments under Article III of this Agreement.
The first Funding Period shall start January 1st, 1996 to December 31, 1996.
15) (( INVENTION )) shall mean any invention or discovery (whether or not
patented or patentable) in the Field of Use which is originated or conceived or
first reduced to practice. Effective January 1, 1996, Inventions shall be
limited to inventions or discoveries (whether or not patented or patentable)
arising from the Research Program.
16) (( KNOW-HOW )) shall mean all technical and other information arising
from the Research Program, including, but not limited to all data, and
information related to, results of experiments, formulae, specification,
procedures, tests, Compounds, cell lines, cultures, constructs, vectors,
development strains, micro-organisms, assay systems, assay protocol and assay
supporting material, fermentation and purification material and techniques.
17) (( LEAD COMPOUND )) shall mean those Compounds emerging from the
Research Program designated by the Program Council for advance scientific
evaluation.
18) (( LICENSE )) shall mean an exclusive license to a Licensed Compound
or Licensed Technology under this Agreement.
19) (( LICENSE AGREEMENT )) shall mean an agreement executed between the
Parties which sets forth the terms under which a Licensed Compound or Licensed
Technology shall be licensed, which agreement shall comply with the provisions
of this Agreement.
20) (( DEVELOPMENT AGREEMENT )) shall mean an agreement executed between
the Parties which sets forth the terms under which a Licensed Compound or
Licensed Technology shall be developed, which agreement shall comply with the
provisions of this Agreement.
21) (( LICENSED COMPOUND )) shall mean a Compound upon which SANOFI has
exercised its Option Right under this Agreement.
22) (( LICENSED TECHNOLOGY )) shall mean a technology or Know-How upon
which SANOFI has exercised its Option Right under this Agreement.
23) (( NET SALES )) shall mean the total of all charges invoiced to
customers by SANOFI, any SANOFI
5
6
Affiliate, and/or its sub-licensees for Licensed Compound less: (a) normal
trade and cas discounts actually allowed; (b) credits or refunds actually
allowed for spoiled, damaged, out-dated, or returned goods; (c) sales and other
excise taxes imposed and paid directly with respect to the sales; (d)
transportation costs paid on behalf of the customer; and (e) commissions and
rebates; provided, however, that sales between SANOFI and any Affiliate shall
not be included in such computations. No sales of Licensed Compound to any
person(s) shall be counted more than once in the calculation of Net Sales.
24) (( PATENT APPLICATIONS )) shall mean any patent applications with
respect to an Invention.
25) (( PATENTS )) shall mean any patents containing a Valid Claim, granted
on or pursuant to Patent applications, including any continuations, renewals,
extensions or re-issues or any divisions thereof.
26) (( RESEARCH PROGRAM )) shall mean the research and pre-clinical
development program as defined in the Research Program attached hereto under
Exhibit A, funded by SANOFI and agreed to by the Parties, being as defined in
the Research Program Plan.
27) (( RESEARCH PROGRAM PLAN )) shall mean a yearly research plan
outlining the goals/objectives, costs, potential funding sources (both SANOFI
requested and external grants), milestones, timelines, and status of
intellectual property.
28) (( SANOFI AFFILIATE )) shall mean any present or future firm, company
or joint venture or other entity which directly or indirectly controls, is
controlled by or is under the common control of SANOFI. "Control" shall mean
the legal power to direct or cause the direction of the general management and
policies of such entity whether through ownership of at least [**]
percent of voting securities, by contract or otherwise.
29) (( SANOFI INFORMATION )) shall mean any and all information and
technology which is applied to or derived from activities conducted by or on
behalf of SANOFI with respect to any Compounds, materials, technologies, or
Know-How, the rights to which are owned by SANOFI.
30) (( SANOFI PROJECTS )) shall mean any work under the Research Program
on Compounds, materials, technologies, or Know-How, the rights to which are
owned by SANOFI, and to which SANOFI controls the decisions on funding and
program protocols.
31) (( TECHNOLOGY )) shall mean all processes, methodologies, tools and
procedures used to develop and/or analyze compounds including but not limited
to cell lines, cultures, constructs, vectors, development strains,
micro-organisms, assay systems, assay protocol and assay supporting material
fermentation and purification material and techniques.
32) (( VALID CLAIM )) shall mean a claim of an issued Patent relating to a
Licensed Compound or CTRC Information held by CTRC during the existence of the
Patent together with any renewals or extensions thereof or a claim of a Patent
Application, which claim has not been declared or rendered invalid by
re-examination, re-issue, disclaimer or unappealable final judgment of a court
of competent jurisdiction. If no Patent has issued within fifteen (15) years
after the earliest filing date of an application, then the claims of such
application will not be considered valid.
ARTICLE II -- RESEARCH PROGRAM/PROGRAM COUNCIL
2.1 During the term of this Agreement, CTRC shall conduct or procure the
conduct of the Research Program under the direction and responsibility of the
Program Council as outlined in the Research Program approved by the
6
7
Program Council.
2.2 During the period of tills Agreement, CTRC shall provide to SANOFI a
written progress report on its work under the Research Program in the preceding
three (3) month period within twenty (20) working days after the conclusion of
such period.
2.3 CTRC and SANOFI shall each designate two (2) representatives to a
council to plan and oversee all scientific and technical matters relating to
the Research Program (the (( Program Council))). The Program Council will
approve budgets and priorities for the work to be conducted under this
Agreement, in accordance with the allocation formula set forth in Article III.
The representatives will elect a chairperson who will schedule at least two (2)
meetings per year, prepare meeting agendas and issue minutes for each meeting.
The Parties will use good faith efforts to reach a consensus on decisions
affecting the Research Program budget and project priorities.
However failing to reach a consensus, it is understood that CTRC shall have a
tie breaking vote for any budget decision up to an amount of [**]
dollars and that SANOFI shall have a tie breaking vote for
any budget decision over [**] dollars. The Program
Council representatives will deal in good faith at all times in attempting to
reach Agreement.
2.4 Upon reasonable notice to CTRC, SANOFI's representative(s) shall have
the fight to visit, at reasonable intervals, CTRC's research sites and
observe CTRC's activities under the Research Program.
2.5 Upon or prior to the execution of this Agreement CTRC will submit to
SANOFI a proposed Research Program including a written list of all current and
proposed research projects within the Field of Use being conducted by CTRC,
which proposal shall contain the approximate funding requirements for each
research project to be considered by SANOFI for funding in calendar year 1996,
said list being attached under Exhibit A. SANOFI will select the projects it
wishes to fired according to the provisions in Article M and so notify CTRC in
writing prior to November 15, 1995. Projects selected by SANOFI, including
SANOFI Projects, shall constitute the Research Program for 1996. Parties
should proceed according to the same terms in 1996 in order to set forth
funding in calendar year 1997.
2.6 Any Acquisition Costs in excess of [**] ($[**]) dollars shall be
discussed and approved with the Program Council prior to being incurred or paid
by CTRC.
During the term of this Agreement and at SANOFI's request, CTRC agrees to the
extent that it is authorized to do so, to review with SANOFI on a confidential
basis New Research Projects (as defined below) in the Field of Use which are
not encumbered by other Parties and which are not included in the Research
Program. In the event SANOFI wishes to fund any of the New Research Projects
or to license, or obtain an Option Right to license CTRC's proprietary rights
to such projects, CTRC agrees to enter into good faith negotiations with SANOFI
to effect such an agreement.
2.7 Current and proposed Research Projects submitted by CTRC to SANOFI for
its review every year shall come with a brief research plan (5-6 pages)
outlining the goals/objectives, costs, potential funding sources (both SANOFI
requested and external grants), milestones, timelines, and status of
intellectual property.
2.8 CTRC agrees to give SANOFI a first right of review of afl new research
projects (New Research Project) in the Field of Use to which CTRC has the legal
right to develop, make, have made, sell or have sold and which were not
mentioned in the Research Program. The New Research Projects will be
introduced at Program Council meetings. SANOFI has a maximum of ninety (90)
days to review such research project and make the following decisions:
7
8
a) SANOFI does not fund said New Research Project; in which event
this New Research Project is unencumbered and CTRC has right to find
additional source of funding; however it is understood that CTRC will
inform SANOFI of any firm offer from third parties and will provide
SANOFI with an additional thirty (30) days to reconsider its decision
to fund this New Research Project.
b) SANOFI agrees to fully fund this New Research Project; in which
event, SANOFI shall then have all rights in the New Research Project
according to the terms and obligations of this Agreement;
c) Parties agree to partial SANOFI funding and obtainment of a
mutually agreed third party co-funder. It is understood that SANOFI
shall be part of all negotiations between CTRC and additional
co-funder of such New Research Projects, and rights and royalties
assigned to SANOFI will be negotiated based on the percentage of
SANOFI's funding under said New Research Projects. Terms and
conditions of said SANOFI's participation to such negotiations shall
be mutually agreed upon between the Parties prior the entering into
discussions with such third party co-funder.
After January 1, 1997, if SANOFI decides to fiend a New Research Project, which
is at the discovery level (the project has not reached the development stage and
as such is not ready to go to the FDA for IND), then SANOFI shall pay to CTRC an
exclusive entrance fee of [**] ($ [**] ) dollars according to the terms of
payment as stated under Article HI. It is agreed between the Parties that said
entrance fee shall be spent to support investment of said New Research Project.
2.9 With respect to projects which have previously been funded by SANOFI
(i.e. pre-clinical development or discovery projects to which CTRC has or may
acquire Commercial Rights), but which have ceased to be funded by SANOFI, then
no later than ninety (90) days after being presented to the Program Council,
the Commercial Rights for such projects, to the extent not otherwise subject to
any rights of SANOFI which preexist this Agreement, shall be excluded from
SANOFI's Option Right.
Ninety (90) days after the presentation of such project to the Program Council,
CTRC shall be free, under suitable confidentiality restrictions, to commence
negotiations with third party with respect to said Commercial Rights to such
projects and SANOFI shall have no further rights in such projects.
2.10. The Program Council shall also be in charge of designating the Lead
Compounds.
2.11. It is understood that CTRC will keep specific note books relating to
the Research Program or any New Research Project proposed to SANOFI, which
shall be received by SANOFI or authorized representatives from time to time
upon two weeks advance written notice by SANOFI to CTRC.
ARTICLE III--CONSIDERATION - TERMS OF PAYMENT
3.1 In consideration of the carrying out of CTRC's general research
responsibilities under the Research Program, and in consideration of the other
duties and obligations of CTRC under this Agreement, and subject to the
termination provisions of Article VII herein, SANOFI shall provide funding to
CTRC with in the amount of three million ($3,000,000) dollars for basic
research and preclinical discovery research in fields related to oncology for
1996, and SANOFI shall provide funding to CTRC in the amount of one million
five hundred thousand ($1,500,000) dollars for basic research and preclinical
discovery research in fields related to oncology for 1997.
3.1.1 Payments by SANOFI to CTRC over the term of the Agreement will be
according to the following schedule:
January 1, 1996 $750,000
April 1, 1996 $750,000
8
9
July 1, 1996 $750,000
October 1, 1996 $750,000
January 1, 1997 $375,000
April 1, 1997 $375,000
July 1, 1997 $375,000
October 1, 1997 $375,000
CTRC shall submit an invoice to SANOFI within 30 days prior to each
payment due date.
3.1.2 a) During the Funding Period beginning January 1, 1996 and ending
December 31, 1996:
i) SANOFI Projects-The Parties, through the Program
Council, will first allocate up to one million dollars
($1,000,000) for each Funding Period to SANOFI Projects.
SANOFI shall control, in its discretion, the planning and
expenditure of such funds.
ii) Other projects-The Parties, through the Program
Council, will allocate two million dollars ($2,000,000) plus
any of the one million ($1,000,000) dollars not dedicated to
SANOFI Projects for calendar year 1996 to fund other research
projects including New Research Projects selected by SANOFI to
be included in the Research Program.
During such a period of time, all payments due under this Agreement
i.e. Option Fee, Licensing Fee and Milestone Payment, as well as under
the MGBG License and Development Agreement, except bonus payments, if
any, shall be credited to SANOFI's funding commitment under this
Agreement for 1996, up to a maximum credit of seven hundred and fifty
thousand dollars ($750,000). In the event the amount due for such
fees and payments exceeds the maximum credit in said period of time,
CTRC, shall then issue a separate invoice for such excess to SANOFI,
which amount shall be payable by SANOFI within thirty (30) days.
b) During the Funding Period beginning January 1, 1997 and ending
December 31, 1997:
i) SANOFI Projects SANOFI will have discretionary
control in planning and expenditure of up to five hundred
thousand dollars ($500,000) of the base funding support (one
million five hundred thousand dollars ($1,500,000)) for use
in support of pre-clinical research or other research and
development work on SANOFI owned or licensed Compounds and/or
Technology.
Subject to prior express and written consent of SANOFI on a
corresponding estimates provided by CTRC, SANOFI agrees to pay
on a fee-for-service, basis any work conducted by CTRC on
SANOFI owned Compounds/Technology that exceeds five hundred
thousand dollars ($500,000).
If the SANOFI budget is less than five hundred thousand
dollars ($500,000), the residual will be allocated to CTRC
research projects. If the amount spent during the fiscal year
is less than five hundred thousand dollars ($500,000), then:
a) a time credit will be issued to SANOFI if due to delays at
CTRC, or b) be allocated to CTRC New Research Project(s) if
due to delays by SANOFI including changes in priorities issued
at the request of SANOFI.
ii) Other projects The Parties will allocate one million
dollars ($1,000,000) plus any of the five hundred thousand
dollars ($500,000) not dedicated to SANOFI Projects for
calendar year 1997 to fund other projects including New
Research Projects selected by SANOFI to be included in the
Research Program. Allocation of funding will be made by the
Program Council.
9
10
c) SANOFI will provide CTRC a research budget for SANOFI directed
research at the beginning of each calendar year (January 1) outlining
its research requests. The first such budget is to be attached
hereinafter under Exhibit B.
3.2 On or after January 1, 1997, the entrance fee of [**]
dollars ($ [**] ) shall be paid to CTRC according to the terms of payment as
stated herein for CTRC New Research Project(s) which are incorporated into the
Research Program.
3.3 SANOFI shall always have the Option to prepay any payments under this
Agreement.
3.4 Save and except licensing and milestones fees, to be paid under a
License Agreement and/or a Development Agreement if any, funds received from
SANOFI, including funds received in case SANOFI decides to enter into a New
Research Project(s) shall be exclusively expended by CTRC in support of the
Research Program and in the conduct of the other duties and obligations of CTRC
under this Agreement.
3.5 Except as otherwise set forth in this Agreement, data, results,
reports and all information contained therein prepared solely by or on behalf
of SANOFI, by a party other than CTRC, which relates to the Research Program,
(including New Research Projects in cases SANOFI decides to enter into it)
including but not limited to SANOFI information, shall remain or become the
exclusive property of SANOFI as well as all data generated on SANOFI Projects.
Except as otherwise set forth in this Agreement, data, results, reports and all
information contained therein prepared by or on behalf of CTRC, in
contemplation of or as a result of performance of this Agreement to the
exclusion of the Research Program, including but not limited to CTRC
Information, shall remain or become the exclusive property of CTRC.
3.6 Notwithstanding other provisions of this Agreement, all Know-How may
be used by either party without restrictions, for non commercial research
purposes only (except for work conducted on SANOFI Projects).
ARTICLE IV - OPTION RIGHT
4.1 GRANT OF OPTION
4.1.1 Upon execution of this Agreement CTRC hereby grants to SANOFI, from
January first 1996 an exclusive option right during the term of this Agreement
as well as during a period of thirty-six (36) months following the termination
of this Agreement to evaluate CTRC Information and obtain a license to any
Commercial Rights which may have accrued under any Research Program, or New
Research Project(s) ((( Option Right ))).
4.1.2 If SANOFI decides to invoke its Option Right or if CTRC decides to
submit to SANOFI for its consideration relative to SANOFI's Option Right a
commercially viable Compound and/or Technology, CTRC shall then provide SANOFI
with a Data/Information Package relative to the Compound or Technology subject
to the Option Right.
a) Upon receipt of a Data/Information Package, SANOFI may
exercise the Option Right by providing to CTRC a written notice of its
intent to exercise its Option Right within the sixty (60) day period,
with respect to its interest in obtaining a license to use CTRC
Information regarding the subject Compound, material, technology or
Know-How, or to support any additional work needed to complete the
Data/Information Package.
If additional time is needed for SANOFI's review or evaluation of a
Data/Information Package, SANOFI
10
11
shall notify CTRC before expiration of the sixty (60) day review
period and state its reasons for seeking an extension of the review
period. If SANOFI's reasons are acceptable to CTRC, which acceptance
will not be unreasonably withheld, the Parties will agree on a
reasonable extension of the review period.
b) If SANOFI elects not to exercise by written notice its Option
Right to license Commercial Rights described in a Data/Information
Package of suitable content and quality, then CTRC, subject to the
terms and conditions of this Agreement shall be free to offer for
license to any third party such Commercial rights, or pursue it for
its own account.
c) In the event that such Data/Information Package, which in the
reasonable exercises of both Parties' judgment, and according to the
knowledge of the pharmaceutical industry state of the art, meets the
criteria of Article 1.1.8., is not of acceptable content and quality
to SANOFI in the reasonable exercise of scientific judgment, SANOFI
may elect to postpone a decision on the exercise of its Option Right
until sufficient work has been completed to provide the
Data/information necessary to meet the criteria of Article 1.1.8.
Such program, subject to SANOFI's express written consent on the cost
of such program, shall be fully funded by SANOFI, and funding which
shall represent the aggregate present value of such funding shall be
fully creditable against future royalties from that Licensed Compound
or Licensed Technology, and SANOFI's Option Right shall be extended
through the funding period.
d) If SANOFI is presented with a Data/Information package which
CTRC believes in good faith to be of suitable content and quality to
meet the criteria of Article 1. 1. 8., but SANOFI believes to be
incomplete or not of acceptable content or quality and SANOFI
expressly declines to fund additional work necessary for such
Data/Information Package, then CTRC may offer such Data/Information
Package to any third party for license and funding support, or pursue
it for its own account. Data/Information packages offered to third
party may not include any of the SANOFI Information without the
written consent of SANOFI, which Agreement shall be granted at
SANOFI's sole discretion.
4.1.3 For all Lead Compounds designated by the Program Council and resulting
from the Research Program or New Research Project(s), entering development and
for which SANOFI decides to exercise its Option Right, the Parties will
negotiate, develop and execute a mutually agreeable written License Agreement,
and Development Agreement as the case may be, SANOFI must exercise its Option
Right for a License Agreement, and Development Agreement as the case may be no
later than the PM submission of said Compound(s).
Notwithstanding any other provision contained herein, if SANOFI decides to
exercise its Option Right with respect to a Lead Compound, then CTRC shall not
grant any license to a third party regarding an Analogue and Counterpart to
said Lead Compound except as may be expressly authorized in the License
Agreement or Development Agreement, as the cas may be.
4.1.4 Upon SANOFI's written notice to CTRC to exercise its Option Right and
the payment of license fees as further described, CTRC will grant to SANOFI an
exclusive, world-wide right and license, with the right to grant sub-licenses,
to possess and utilize such CTRC Information as is necessary for the
development and commercialization of Licensed Compounds or Licensed
technologies in the Field of Use. Such right and license includes exclusive
licenses within the Field of Use under any Patents, Patent Applications,
continuations, continuations in-part and foreign equivalents of same owned by
or assigned to CTRC pertaining to Licensed Compounds or Licensed Technologies.
4.1.5 SANOFI, which shall retain the full authority and responsibility for
defining and conducting the development of a Licensed Compound or Licensed
Technology, shall be entitled, at its discretion, to provide development work
to CTRC according to SANOFI currents and anticipated needs. SANOFI
acknowledges that
11
12
CTRC possesses expertise in the field of oncology compound development and
accordingly SANOFI, on a case by case basis, will in good faith consider the
opportunity, to enter into a Development Agreement with CTRC.
If Parties so decide the Development Agreement and therefore development work
plan shall be as mutually agreed between the Parties. In case the Parties
cannot agree on the tenons of a Development Agreement or a development work
plan SANOFI shall be entitled to enter into such development work with any
third party of its choice. It is understood that SANOFI agrees to use all
reasonable efforts and diligence to diligently develop the Licensed Compound or
the Licensed Technology according to SANOFI's current business strategy.
4.2 EXERCISE OF OPTION RIGHT.
4.2.1 EXERCISE OF OPTION RIGHT ON COMPOUND(S):
(a) Following SANOFI's written notification of its exercise of its Option
Right for a Licensed Compound, and payment of the license fee as provided
hereinafter, the Parties shall negotiate in good faith and execute a License
Agreement, and/or a Development Agreement, if any, for such compound.
(b) The License Agreement, and/or the Development Agreement if any, shall
contain, among other provisions relative to, (i) an agreed development plan, in
case a Development Agreement is entered into), (h) reimbursement and assumption
by SANOFI of Acquisition Costs, (iii) diligence requirements, (iv) development
responsibilities if any, of the Parties and the Program Council, and (v)
provisions for termination, licensing fees, milestone payments and royalties,
as set forth hereinafter.
c) The License Agreement, and/or the Development Agreement if any, shall
be executed within one hundred and twenty (120) days of written exercise of
SANOFI's Option Right. In the event that Parties are unable to reach an
Agreement with respect to particular substantive term or terms of the License
Agreement and/or Development Agreement if any, the Parties agree that the
dispute shall be resolved by reference to the immediately preceding, License
Agreement and/ or Development Agreement, if any, executed between the Parties.
(d) The License shall be effective upon payment of the license fee as
provided hereinafter, regardless of whether the License Agreement, and
Development Agreement if any, has been formally executed by the Parties. In
the event, the Parties are unable to agree to a written Agreement after
utilizing the procedure of Section 4.2. 1 (c) above, the Parties shall submit
the matter to binding alterative dispute resolution mechanism (as selected by
the Parties) to resolve such differences; or, at SANOFI's written request, CTRC
shall return the license fee to SANOFI. In such event, CTRC, with respect to
the terms of this Agreement, shall be free to offer such Commercial Rights to a
third party or pursue it on its own account, without further obligation to
SANOFI.
4.2.2 EXERCISE OF OPTION ON TECHNOLOGY:
(a) Following SANOFI's written notification of its intent to exercise its
Option Right for Technology, the Parties shall negotiate in good faith in order
to execute License Agreement, and/or Development Agreement as the case may be,
for such Technology.
(b) In agreeing to the terms of the License Agreement and/or Development
Agreement for the Technology, the Parties will consider, among other things,
competing technologies, the potential market for the Technology or services
enabled by the Technology, and the costs/benefit of the resulting Technology or
services. The Agreement shall contain provisions for licensing fees, if any,
reimbursement of Acquisition Costs, development responsibilities if any, and
provisions for milestone payments and royalties, as set forth hereinafter.
12
13
(c) The License Agreement, and/or Development Agreement as the case may
be, for a Licensed Technology will be executed within one hundred twenty (120)
days of written notice of SANOFI's intent to exercise its Option Right. Upon
execution of such Agreement, SANOFI shall pay the license fee, if any, for such
Licensed Technology.
(d) If the Parties are unable to reach an Agreement on a License
Agreement, and/or Development Agreement if any, for such Technology, after good
faith negotiations, as set forth above, then CTRC shall be free to negotiate
with third party with respect to such Technology; provided that, the terms of
any technology license offered to any third party by CTRC may not materially
differ from the terms offered to SANOFI.
4.3. FEES, MILESTONES, PAYMENTS AND ROYALTIES.
4.3.1. LICENSING FEE: The licensing fees, which shall be paid upon due
execution, of the corresponding License Agreement and which are inclusive of
the fees under a Development Agreement if any, to be paid by SANOFI to CTRC are
as follows:
(a) [**] dollars ($ [**] ) for a Licensed Compound if
the leading indication as specified in the corresponding License Agreement
and/or Development Agreement if any, is used in the treatment of breast,
colorectal or non-small cell lung cancer (hereinafter Major Indications); or
(b) [**] dollars ($ [**] ) for a Licensed Compound
if the leading indication, as specified in the corresponding License Agreement,
and/or Development Agreement, if any, is intended for use in the treatment of
any cancer, other than breast, colorectal or non-small cell lung, up to a
maximum of two such indications for a Licensed Compound;or
(c) For Licensed Technology, the Parties will negotiate in good faith
appropriate licensing fees, if any, considering competing technologies, the
potential market for the services enabled by the Technology, and the
cost/benefit of the resulting services.
(d) Licensing Fees on Analogues and Counterparts to Licensed Compounds,
which shall be paid by SANOFI to CTRC upon due execution of an appropriate
Licensing Agreement, Development Agreement and/or amendment thereto, if any,
are as follows:
(i) [**] ($ [**] ) dollars for Analogues and Counterparts
to a Licensed Compound for such indication as agreed between the Parties in the
corresponding. License Agreement, and Development Agreement, if any, and
(ii) Based upon the type of indication, [**] dollars
($ [**] ) for Major Indication, or [**] dollars
($ [**] ) for other indications, will be paid at the time of receipt of NDA
approval or equivalent for said Analogues and Counterparts to Licensed
Compound.
(e) The total amount of Licensing Fee to be paid by SANOFI shall in no
case exceed [**] dollars ($ [**] ) for each Compound or
Technology. Example: If SANOFI exercises its Option Right to license a
Compound or Technology which is intended for the treatment of breast cancer, as
well another indication such as prostate cancer, CTRC is entitled only to a
license fee of the Major Indications that being [**] dollars
($ [**] ) for breast cancer. No additional license fee need to be paid by
SANOFI for the indication of prostate cancer.
13
14
4.3.2. MILESTONE PAYMENTS: Upon achievement of any development or
commercialization defined hereinafter, SANOFI will pay to CTRC a Milestone
Payment as specified below:
a) Upon the first pre-NDA meeting as agreed upon between the
Parties, pre-CLA, or equivalent by SANOFI or CTRC for each Licensed
Compound in each of the U.S., Japan or one of the first major
countries of the European Union (EU) (i.e. France, United Kingdom,
Germany), SANOFI will pay to CTRC a global lump sum Milestone Payment
of [**] dollars ($ [**] ); and
b) Upon receipt by SANOFI or CTRC of an approval to sell
commercially each Licensed Compound or Licensed Technology in the
U.S., Japan or the first major country of the EU for each new approved
indication, for a maximum of two such indications, SANOFI will pay to
CTRC a milestone payment according to following principles:
1st (US or Japan or first Major EU Country) $ [**] ($)
2nd $ [**] ($)
3rd $ [**] ($)
The total amount of milestone payments per Licensed Compound or Licensed
Technology to be paid by SANOFI shall in no case exceed [**]
dollars ($ [**] ).
4.3.3. ROYALTIES.
a) For each Licensed Compound sold by SANOFI, Affiliate or sub-licensee,
SANOFI will pay to CTRC royalty payments of [**] percent ([**]) (said royalty be
inclusive of any license fee or royalty which may be incurred by CTRC) on Net
Sales of such Compound as follows. Such royalties will be paid until the last
to expire of all Valid Claims for that Licensed Compound or market exclusivity
for that Licensed Compound winch has been obtained by statutory or regulatory
grant or decree, such as the Drug Price Competition and Patent Term Resolution
Act of 1984 or foreign counterpart. However it is understood that for each
Licensed Compound not covered by a Valid Claim or market exclusivity such
royalties will be paid until ten (10) years after the date of First Commercial
Sale for that Licensed Compound.
b) For each Licensed Technology covered by one or more Valid Claims, the
Parties will negotiate in good faith an appropriate royalty, taking into
consideration competing technologies, the potential market for the Technology
or services enabled by the technology and the cost/benefit of the resulting
Technology or services. Such royalties will be paid until the last to expire
of all Valid Claims for that Licensed Technology or market exclusivity for that
Licensed Technology which has been obtained by statutory or regulatory grant or
decree, such as the Drug Price Competition and Patent Term Resolution Act of
1984 or foreign counterpart. However it is understood that for each Licensed
Technology not covered by a Valid Claim or market exclusivity such royalties
will be paid until ten (10) years after the date of First Commercial Sale for
that Licensed Technology.
c) Starting with the first calendar quarter ending at least sixty (60)
days after the First Commercial Sale of a Licensed product meaning a Licensed
Compound or Licensed Technology (Licensed Product), SANOFI shall make written
financial reports and royalty payments to CTRC within thirty (30) days after
the end of each calendar quarter. Such reports shall state the number,
description and aggregate Net Sales of Licensed Compounds and/or Technologies,
as the case may be, during such completed calendar quarter, and the resulting
calculation of earned royalty payments due to CTRC for such completed calendar
quarter. With each such report SANOFI shall include payment due to CTRC of all
royalties for the calendar quarter covered by such report. The remittance of
royalties payable on Net Sales of Licensed Compounds and/or Technologies, as
the case may be, shall be made to CTRC at the official rate of exchange of the
currency of the country from which the
14
15
royalties are payable, as quoted by the Wall Street Journal (or in the event
there is no Wall Street Journal quote for such currency, the rate of exchange
shall be established by the issuer of such currency) for the last business day
of the calendar quarter in which the royalties are payable; less any
withholding or transfer taxes which are applicable. SANOFI shall supply CTRC
with proof of payment of such taxes paid on CTRC's behalf and shall cooperate
with CTRC in obtaining credit or refund of any such taxes. The Parties shall
cooperate with each other in making lawful arrangements in the event royalties
payable by SANOFI are earned in a country whose currency is blocked on exchange
into U.S. Dollars. Whenever any payment hereunder shall be stated to be due
on a day that is not a business day such payment shall be made on the
immediately succeeding business day.
d) SANOFI shall promptly notify CTRC in writing of all submissions to
appropriate regulatory authorities for approvals to sell Licensed Products in
any country ; of the date such approvals are granted : and the date of the
First Commercial Sale of such Licensed Compounds and/or Technologies, as the
case may be, under this Agreement.
e) SANOFI shall keep true and accurate records and books of accounts
containing all data necessary for the calculation of the royalties payable to
CTRC under this Agreement. Such records and books of account for the prior
three (3) year period shall be made available at SANOFI's principal office in
FRANCE on reasonable notice at all reasonable times during SANOFI's normal
business hours for inspection by an independent auditor on behalf of CTRC or by
an authorized office or CTRC.
4.4. CTRC IN-LICENSED COMPOUNDS
Compounds that are in-licensed to CTRC and then are offered to SANOFI as
potential co-development candidates, shall have a written License Agreement,
and Development Agreement plan as the case may be, with a specific and
appropriate milestone and royalty schedule to be negotiated in good faith
between the Parties.
4.5. REIMBURSEMENT
CTRC agrees to reimburse SANOFI for costs under Research Programs which have
been funded after the date of the First Invention which relate to Compound(s)
and/or Technology for which SANOFI has decided not to exercise its Option Right
which Compound(s) and/or Technology have been licensed by CTRC.
The amount of reimbursement to be paid by CTRC to SANOFI shall be equal to the
total amount by which SANOFI funded the costs after the Date of First
Invention, for said Compound or Technology, said amount being adjusted for
inflation and SANOFI shall only be reimbursed to the extent that CTRC receives
royalties on the marketed Compounds or Technology, but not to exceed, [**] per
cent ([**]) per year of world-wide Net Sales of said Compounds and Technology
and CTRC shall obligated to pay SANOFI upon its receipt of payment of its
royalties for said Compound or Technology.
ARTICLE V--CONFIDENTIALITY
5.1 CTRC and SANOFI recognize that the conduct of the Research Program may
require the transfer of Confidential Information between the Parties.
It is therefore agreed that each Party shall retain in confidence the
Confidential Information of the other Party during the term of this Agreement
and for a period of ten (10) years from the date of receipt of the information.
Each Party shall not use such Confidential Information for any purpose except
as permitted in this Agreement and shall not disclose such Confidential
Information to any Third Party, other than Affiliates, or third party who agree
15
16
to be bound by similar confidentiality provisions as contained in this article,
except as permitted by this Agreement.
5.2 The term (( Confidential Information )) as used herein in the case of
documentary information, shall mean that documentary information which is
marked as confidential at the time when it is given to the receiving party.
Confidential Information which is originally orally disclosed and identified as
confidential shall include only that information which is identified as
Confidential Information by written communication from the disclosure to the
recipient sent within thirty (30) days after it is originally disclosed in
oral, non-tangible form.
5.3 The term "Confidential Information" shall not include:
a) Information which was in the public domain at the time of
disclosure;
b) Information which after disclosure, becomes part of the public
domain through publication or otherwise, except by breach of
this Agreement;
C) Information which the recipient can demonstrate based on
written records was already in its possession prior to its
disclosure under this Agreement; or
d) Information which any Party receives from an independent third
party which has the right to disclose it to such Party.
5.4 The obligations of confidentiality set forth herein shall not apply to
any information to the extent that such information:
a) Is required to be disclosed by order of a court of law or
appropriate government agency or otherwise required by law;
b) Is submitted to governmental agencies to facilitate the
issuance of marketing approvals for Licensed Compounds or
Licensed Technologies;
c) Is reasonably required to be disclosed to third party such as
patent agents in the filing, prosecution and issuance of
Patents as permitted under the terms of this Agreement;
d) Has been approved for publication by the Parties; or
e) Is Compound-related information which is reasonably required
to be disclosed in connection with marketing or sublicensing
activities with respect to Compounds.
ARTICLE VI-PUBLICATION AND PUBLICITY
6.1 The right of publication or oral presentation, including the results
from the Research Program related to this Agreement, shall be subject to prior
review and approval by the SANOFI's publication procedure committee (the
Committee), in order to review for concerns such as potential Confidential
Information or patentable information. Such review will be completed within
thirty (30) days from the date of receipt by the Committee of publication
demand, and such approval will not unreasonably be withheld.
Failure by the Committee to act within thirty (30) days of receipt of a
publication or presentation proposal shall be deemed an approval by the
Committee. After approval, Patent Application filings by either Party shall be
the responsibility of the respective Party.
16
17
6.2 CTRC and SANOFI agree that they will not make any public
announcements, press releases or otherwise publicize the contents of this
Agreement, the relationship of the Patties hereunder, or any work to be
conducted hereunder without first obtaining prior written approval of the other
party. Further, no party shall use the name of the other party in any form of
publicity, advertising or promotion without the written permission of that
party.
ARTICLE VII--TERMINATION OR EXTENSION
7.1 This Agreement shall terminate on December 31, 1997, unless earlier
terminated or extended for an additional one (1) year period by mutual written
Agreement of the Parties. It is however understood that if Parties intend to
extend this Agreement under the same terms and conditions as set forth herein
such extension decision shall be agreed upon in writing no later than ninety
(90) days before the aforementioned termination date.
7.2 If the Parties decide to modify terms and conditions of this
Agreement, prior to its termination in order to effectuate an extension and/or
renewal of this Agreement, seventy-five (75) days prior to the termination date
of this Agreement, the Parties shall mutually consent in writing to extensions
of this Agreement. The terms and conditions of such extensions are to be
negotiated and agreed upon by the Parties within forty-five days (45) of such
mutual consent, but in no event later than seventy-five (75) days after the
such mutual consent.
7.3 Either SANOFI or CTRC may terminate this Agreement by notice in
writing to the other if the other commits a material breach of this Agreement
which, in the case of a breach capable of remedy, shall not have been remedied
within thirty (30) days of the receipt by the other of notice identifying the
breach and requiring its remedy.
7.4 If CTRC suffers a substantial inability to perform its obligations
under this Agreement, the Parties will meet in good faith to determine if such
deficiencies can be corrected in a reasonable period of time. If no reasonable
correction is available, then SANOFI will have the right, upon three (3) months
notice to terminate this Agreement. The Parties will, in good faith, decide if
termination can be accomplished sooner, in a manner which will not disrupt
CTRC's future business.
7.5 In the event of termination of this Agreement, the rights and
obligations of the Parties which have accrued up to such time shall survive and
remain enforceable, including, but not limited to Articles IV, V, VI, VIII of
this Agreement.
ARTICLE VIII-INVENTIONS AND PATENTS
8.1 SANOFI Inventions
CTRC recognizes that the SANOFI's Information and/or broadly speaking all
materials furnished by SANOFI if any under this Agreement are the sole and
exclusive property of SANOFI, and accordingly CTRC agrees to use said SANOFI's
Information and/or materials only to perform its obligations under the present
Agreement.
All Inventions developed solely by SANOFI or with a third party shall be the
sole and exclusive property of SANOFI. The industrial exploitation by SANOFI,
if any, will, therefore, not entitle CTRC to any royalties or other
indemnities. In any such case SANOFI shall be the sole and exclusive owner of
the results generated by this Agreement on SANOFI's Information/Projects.
8.2 Joint Inventions- All Inventions developed jointly by CTRC and SANOFI
shall be the property of CTRC and SANOFI, subject to the provisions of this
Agreement and the Option Agreement. If SANOFI exercises its Option
17
18
Right, SANOFI, at its discretion shall be responsible for filing and
prosecuting all Patent Applications for afl Joint Inventions. Alteratively,
SANOFI can fund such costs through the Research Program Funding. If SANOFI
elects not to prosecute a potentially patentable Joint Invention, then CTRC, at
its discretion and expense, may seek patent protection for such Invention.
CTRC and SANOFI each grants to the other a non-exclusive, royalty free,
world-wide license to use such Joint Inventions for each party's own research
purposes.
8.3 CTRC Inventions- All Inventions developed solely by CTRC shall be the
property of CTRC subject to the provisions of the SANOFI Option Right. CTRC
agrees to prepare a record of invention in writing of any Invention made within
the Field of Use, and arising from the Research Program which is potentially
patentable and shall submit same to SANOFI for notification and review. CTRC
shall be responsible, at its discretion, for filing and prosecuting Patent
Applications for all CTRC Inventions. If CTRC elects not to prosecute a
potentially patentable Invention, then SANOFI, at its discretion and expense,
may seek patent protection for such Invention.
8.4 CTRC agrees to have executed by its employees or any contractors or
individuals working on Research Program, appropriate documents submitted by
SANOFI to obtain, perfect or maintain title to CTRC Inventions and Joint
Inventions. CTRC agrees also to cause its employees to furnish information and
data in their possession reasonably necessary to maintain such Patents in
accordance with the provisions of this Agreement.
8.5 The Program Council will coordinate mutual patent strategy between the
Parties in order to effectuate the purposes of this Agreement and the possible
License Agreement, it being understood that with regard to CTRC Inventions,
CTRC shall bear cost related to patent application, divisions, continuations or
reissue thereof.
8.6 Subject to the confidentiality provisions of this Agreement, SANOFI
and/or any other third party duly appointed by SANOFI, shall be entitled within
thirty (30) days from the date of execution of this Agreement to perform a
intellectual property review of the current work of CTRC under the Research
Program. All such visits shall be of reasonable duration during normal
business hours upon two weeks advance written notice by SANOFI to CTRC.
ARTICLE IX-WARRANTIES AND INDEMNIFICATIONS
9.1 Each party hereby represents that as of the date of this Agreement it
has the full right and authority to enter into and perform this Agreement, and
that each party is free of any duties or obligations to third party which may
conflict with the terms of this Agreement.
9.2 Each party shall defend, indemnity, and hold harmless the other party
and as much as they are concerned its affiliates from any and all claims,
losses, expenses, costs or damages arising from or related to any breach of a
party's obligations, or any negligent act, fault, or omissions of said party
under this Agreement. However SANOFI shall not be liable to CTRC or its
affiliates, nor shall CTRC be liable to SANOFI or its affiliates, for any
indirect incidental or consequential damages, including but not limited to loss
of profit, benefits or goodwill.
9.3 Both Parties, SANOFI and CTRC represent and warrant to the other party
that the Inventions, Know-How results, data, documents, trademark, copyrights
and information provided by each party and used in performance of this
Agreement, do not infringe any third party copyrights or other industrial
property rights.
Accordingly, each party shall defend, indemnity, hold ham-Jess and protect the
other party against any and all claims which might be based on the alleged
infringement of third party copyrights or other industrial property rights as a
consequence of the use and/or disposal in any manner of the Inventions,
Know-How results, data, documents, trademark, copyrights and information
provided by said party under this Agreement.
9.4 CTRC and SANOFI each warrants that it will comply with all applicable
laws and regulations in connection
18
19
with its performance of this Agreement, including the Food, Drug and Cosmetic
Act and the Animal Health Welfare Act.
ARTICLE X-INDEPENDENT CONTRACTOR
In the performance of this Agreement, the status of CTRC, including its
employees and agents, shall be that of independent contractors and not as
employees, agents, or fiduciaries of SANOFI and as such have no right to make
commitments for or on behalf of SANOFI.
ARTICLE XI--ASSIGNMENT
11.1 Subject to the provision of Article 11.2 and 11.3 below, no party to
this Agreement shall assign to any third party the benefit and/or burden of
this Agreement without the prior written consent of the other, which consent
shall not be unreasonably withheld.
11.2 CTRC shall be entitled, with the consent of SANOFI which shall not be
unreasonably withheld, to assign, transfer, or in any manner provide, in whole
or part, the benefit and/or burden of this Agreement to a subsidiary or CTRC
Affiliate or the University of Texas Health Science Center at San Antonio.
Provided that such CTRC Affiliate, subsidiary, or UTHSCSA undertakes and agrees
in writing to assume, observe, and perform the rights and powers and/or duties
and obligations of CTRC under the provisions of this Agreement, being assigned,
transferred or otherwise provided.
11.3 SANOFI shall be entitled, with prior notice to CTRC, to assign,
transfer, or in any manner provide, in whole or part, the benefit and/or burden
of this Agreement to any subsidiary or SANOFI Affiliate or company with which
it may merge or form a joint venture with provided that such SANOFI Affiliate
or other company undertakes and agrees in writing to assume, observe and
perform the rights and powers and/or duties and obligations of SANOFI under the
provisions of this Agreement being assigned, transferred or otherwise provided.
SANOFI shall be entitled, with CTRC's prior consent, which shall not be
unreasonably withheld, to assign, transfer, or in any manner provide, in whole
or part, the benefit and/or burden of this Agreement to a third party.
ARTICLE XII--GOVERNING LAW AND ARBITRATION
The validity, interpretation, construction and performance of this Agreement
shall be governed by the laws of the state of New-York.
Any dispute arising in connection with or out of the performance or the
interpretation of this Agreement, which the Parties cannot settle amicably
shall be finally settled under the Rules of Conciliation and Arbitration of the
International Chamber of Commerce, which Rules are deemed to be incorporated by
reference into this clause.
The Board of arbitrators which shall convene in New-York (USA and shall be
conducted in English language, shall be made of three arbitrators, each party
shall appoint one arbitrator of its choice, and third arbitrator shall be
designated by the two other arbitrators.
19
20
ARTICLE XIII--NOTICE
13.1 Any notice or other document to be given under this Agreement shall be
in writing and shall be deemed to have been duly given if left at or sent by
mail by: a) First class, registered, express or air mail, or b) Telex,
facsimile or other electronic media to a party at the address or facsimile
number set out below for such party or such other address as the party may from
time to time designate by written notice to the other:
Address of SANOFI
SANOFI RECHERCHE,
000 xxx xx Xxxxxxxxxx J. BLAYAC
34184 Montpellier Cedex 04 FRANCE
Attention: Xxxxxx XXXX
Copy to: Legal Department
SANOFI PHARMA
00-00 Xxxxxx Xxxxxxx
00000 - XXXXXXXX Cedex, FRANCE
Address of CTRC
CTRC Research Foundation
0000 Xxxxxxxxx, Xxxxx 0000
Xxx Xxxxxxx, Xxxxx 00000 X.X.X.
Attention: Xx. Xxxxx X. XXXXXX
Copy to:
Xxxxx XXXXXX
Xxx & Xxxxx Incorporated
000 X. Xxxxx, Xxxxx 0000
Xxx Xxxxxxx, Xxxxx 00000
ARTICLE XIV--MISCELLANEOUS
14.1 ENTIRE AGREEMENT.
This Agreement, and its Exhibits, and any License Agreement, and Development
Agreement as the case may be, executed contemporaneously herewith, embody and
set forth the entire Agreement and understanding of the Parties and supersede
all prior oral and written Agreements, understanding or arrangements relating
to the subject matter of this Agreement, it being understood that all
Invention, Know-How, Technology in the Field of Use, arising out of the
previous Research Collaboration Agreement signed between the Parties October 1,
1992 and for which SANOFI is otherwise entitled to exercise its Option Right
under said agreement shall be covered by this Agreement.
14.2 AMENDMENT.
This Agreement shall not be modified or amended without a written instrument
executed by CTRC and SANOFI.
14.3 WAIVER.
No failure or delay on the part of any Party hereto to exercise any right or
remedy under this Agreement shall be
20
21
construed or shall operate as a waiver thereof, neither shall any single or
partial exercise of any right or remedy, under this Agreement preclude the
exercise of any other right or remedy not preclude the further exercise of such
right or remedy as the case may be.
14.4 SEVERABILITY.
If any term or provision of this Agreement or the application thereof to any
party, person or circumstance shall, to any extent, be invalid or
unenforceable, the remainder of this Agreement, or the application of such term
or provision to any party, person or circumstance other than those as to which
it is held invalid or unenforceable, shall not be affected thereby, and each
term and provision of this Agreement shall be void and enforced to the fullest
extent permitted by law.
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement:
SANOFI
BY XX. XXXX-XXXXXXXX XXXXXX BY XX. XXXXXX LE FUR
TITLE PRESIDENT TITLE DIRECTOR RESEARCH & DEVELOPMENT
DATE: DATE:
----------------------------- --------------------------------
CTRC
BY: MR. XXXXX XXXXXX
TITLE CHIEF OPERATING OFFICER
DATE:
----------------------------
21
22
EXHIBIT A
LIST OF CTRC RESEARCH PROJECT
22
23
CTRC/IDD RESEARCH PROJECT PROPOSALS - 1996
PRINCIPLE SANOFI $ 1996
PROJECT PROPOSAL INVESTIGATOR(S) DECISION FUNDING
----------------------------------------------------------------------------------------------------------------------
To Identify Novel Telomerase Inhibitors S-F. Chen Fund
from the Sanofi Winthrop Library
Automated Telomerase Inhibitor Assay & D. Sun Fund
Associated Purificaiton of Telomerase
Design Nucleoside/Nucleotide Analog as S-F. Chen Not Funded ---
Telomerase Inhibitors
Rational Approach to the Design of X. Xxxxxxx & X. Xxxxxx Fund
Telomerase Inhibitors
Characterization of the Telomerase X. Xxxxxx Fund Pending Revision
Target
Telomerase & Telomerase in Primary and X. Xxx Xxxx Fund
Metastic Human Tumors
Evaluation of Sanofi Compounds in Viro X. Xxxxxx Fund as Sanofi Directed ---
Project
Development of New In Vivo Models X. Xxxxxx Fund as Sanofi Directed ---
Project
Evaluation of Sanofi Directed Research S-F. Chen Fund as Sanofi Directed ---
Compounds Using Various In Vivo Studies Project
Evaluation of Sanofi Winthrop Compounds X. Xxx Xxxx Fund as Sanofi Directed ---
in the Human Tumor Cloning Assay Project
Oxaliplatin-Induces Lesions in Cellular X. Xxxxxxxxxxx Fund as Sanofi Directed ---
DNA Project
Optimizing the Antitumor Activity of X. Xxx Xxxx Fund Pending Revision & ILEX
MGBG Approval
Induction of Apotosis by MGBG X. Xxx Xxxx Fund with Revision & ILEX
Approval
Exploitation of Novel Leads in the X. Xxxxxx Not Funded ---
Naphthalimide Series (AB Series) of
Compounds
Topoisomerase II Inhibitors Based on X. Xxxxxx & X. Xxxxxx Not Funded ---
Breaking the Symmetry of
Quinobenzoxazine-Mg2+2:2 Dimers
Targeting of a Unique Subgroup of PT- X. Xxxxxx Fund with Revision
DNA Lesions: The Rational Design of a
New Platinum Chemotherapeutic Agent
BCL-2 as a Target for DNA-Reactive X. Xxxxxxxxxxx Not Funded ---
Agents
DNA Topoisomerase I-targeted Therapy S-F. Chen Fund
for Prostate Cancer
Transcription Complexes as Targets for X. Xxx Not Funded ---
Selective Intervention of Specific Gene
Expression
Extrachromosomal DNA X. XxXxxx & X. Xxxxxxxx Not Funded ---
Human Helicase and Ligase as Novel D. Sun Not Funded ---
Targets
GRAND TOTAL $
23
24
EXHIBIT B
RESEARCH BUDGET SANOFI DIRECTED PROJECTS
25
25
1996 SANOFI DIRECTED RESEARCH AT CTRC/IDD
Project (brief description of studies) Unit Costs Cost per Project
------------------------------------------------------------------------------------------------------------------------
NEUROPEPTIDE RECEPTOR ANTAGONIST
In Vitro MTT Combination Assays - 6 compounds x 4 cell lines @$531 $
New In Vitro Model Development - 3 new models @$1,985
Receptor Studies - 4 compounds, 2 cell lines @5,000 (subcontracted)
In Vivo Evaluations - 2 xenografts, 4 compounds; separately
NEUROPEPTIDE RECEPTOR ANTAGONIST PROJECT SUBTOTAL
MDR REVERSING AGENTS
In Vitro MTT Combination Assays - 5 cell lines @$500
New In Vitro Model Development - 3 new models @$1,985
In Vivo Evaluations - 3 compounds, 2 xenografts, 2 murines,
simultaneously
MDR REVERSING AGENT PROJECT SUBTOTAL
OXALIPLATIN
Mechanism of Action Studies - X. Xxxxxxxxxxx proposal
In Vivo Evaluations - 4 xenografts, combination studies @$23,667
OXALIPLATIN PROJECT SUBTOTAL
CLOPIDOGREL ENANTIOMER
In Vivo Evaluations - 1 xenograft, 1 murine, 1 compound
CLOPIDOGREL ENANTIOMER PROJECT SUBTOTAL
ELASTASE INHIBITOR
In Vivo Evaluations - 1 xenograft, 1 murine, 1 compound
ELASTASE INHIBITOR PROJECT SUBTOTAL
IN LICENSE CANDIDATES
In Vitro MTT Combination Assays - 3 compounds, 3 cell lines @$500
In Vitro Clonogenic Combin. Assays - 3 compounds, 3 cell lines @$1,526
In Vivo Evaluations - 3 compounds, 2 xenografts, 2 murines; separately
IN LICENSE CANDIDATES PROJECT SUBTOTAL
THIOXANTHONE ANALOGUES
In Vivo Evaluations - 2 compounds in 3 xenografts
THIOXANTHONE ANALOGUES PROJECT SUBTOTAL
HUMAN STEM CELL EVALUATIONS
Yearly Volume - 6 compounds in 200 evaluable tumors, 1-hour and
continuous exposure @$37
HUMAN STEM CELL EVALUATIONS PROJECT SUBTOTAL
CONTINGENCY FUNDING FOR PRICE ADJUSTMENTS/UNFORSEEN WORK
GRAND TOTAL
26
